Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - letrozole, quantity: 2.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; maize starch; sodium starch glycollate type a; colloidal anhydrous silica; hypromellose; microcrystalline cellulose; titanium dioxide; purified talc; iron oxide yellow; macrogol 400 - indicated for the treatment of post menopausal women with hormone receptor positive breast cancer. . the safety and efficacy of neoadjuvant use of letrozole has not been established. letrozole is not indicated in hormone receptor negative disease.

Malta - English - Medicines Authority

novartis ireland limited vista building, elm park, merrion road, ballsbridge, dublin 4,, ireland - letrozole - film-coated tablet - letrozole 2.5 mg - endocrine therapy

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis ireland limited - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - letrozole - film-coated tablet - 2.5 milligram(s) - aromatase inhibitors; letrozole

Ireland - English - HPRA (Health Products Regulatory Authority)

originalis b.v. - letrozole - film-coated tablet - 2.5 milligram(s) - letrozole

Israel - English - Ministry of Health

novartis israel ltd - letrozole - film coated tablets - letrozole 2.5 mg - letrozole - letrozole - femara (letrozole tablets) is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whome hormone receptor status cannot be determined locally advanced or metastatic breast cancer. femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - letrozole - film coated tablet - 2.5 milligram - aromatase inhibitors

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing - letrozole - film coated tablet - 2.5 milligram

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - letrozole 2.5mg;   - film coated tablet - 2.5 mg - active: letrozole 2.5mg   excipient: colloidal silicon dioxide hypromellose as 0.087 mg pigment suspension white + 0.087 mg pigment suspension yellow + 1.663 mg additional iron oxide yellow lactose monohydrate macrogols magnesium stearate maize starch microcrystalline cellulose purified talc sodium starch glycolate titanium dioxide - adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer extended adjuvant treatment of invasive early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy for five years. first-line treatment in postmenopausal women with advanced breast cancer advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status, who have previously been treated with anti-oestrogens.